垂体催乳素腺瘤患者妊娠期服用溴隐亭安全性的系统评价

Meta-analysis on Safety of Bromocriptine in Pregnancy Patients with Pituitary Prolactin Adenoma

目的:系统评价垂体催乳素腺瘤患者妊娠期服用溴隐亭的安全性。方法:计算机检索PubMed、Cochrane library、中国期刊网全文数据库(CNKI)、万方数据库、维普数据库、CBM数据库等,按照纳入与排除标准筛选垂体催乳素腺瘤患者妊娠期服用溴隐亭的队列研究和病例对照研究,采用纽卡斯-渥太华量表评价纳入研究的质量,并采用RevMan 5.3软件进行文献荟萃(Meta)分析。结果:共纳入5篇队列研究,合计528例患者。Meta分析结果显示,溴隐亭暴露组患者流产发生率显著低于非暴露组,差异有统计学意义(P<0.05);而在早产、新生儿低体质量及畸形的发生率方面,两组的差异均无统计学意义(P>0.05)。结论:垂体催乳素腺瘤患者妊娠期服用溴隐亭不会增加早产、新生儿低体质量及畸形等不良结局,并可减少流产的发生风险。

OBJECTIVE ：To systematically evaluate the safety of bromocriptine in pregnancy patients with pituitary prolactin adenoma. METHODS： PubMed, Cochrane library, CNKI, WanFang, VIP, CBM database were retrieved by computers to collect the cohort study and case-control study of pregnancy patients with pituitary prolactin adenoma according to the research criteria. Newcastle-Ottawa scale was adopted to evaluate the quality of included literatures, and Meta-analysis was conducted by Rev Man 5.3. RESULTS： Totally 5 case-control studies were involved, including 528 patients. According to Meta-analysis, the incidence of abortion in bromocriptine exposed group was significantly lower than that of unexposed group, with statistical significant difference （ P 〈 0. 05 ）. In terms of weight of newborns and fetal malformation, there was no statistical significance between two groups （P 〉 0. 05 ）. CONCLUSIONS： Bromocriptine in pregnancy patients with pituitary prolactin adenoma will not increase adverse fetal outcomes aspremature birth, low weight of newborns and fetal malformation, and can reduce the risk of abortion.